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Abstract
Background: Vaginal candidiasis is frequent among pregnant women and it is treated with anti-fungal medication
(conazoles). Conazoles have anti-androgenic properties and prenatal exposure in rodents is associated with a
shorter (less masculine) anogenital distance (AGD) in male offspring. To our knowledge this has never been
studied in humans.
Method: In the Odense Child Cohort pregnant women residing in Odense municipality, Denmark, were recruited
at gestational age 8–16 weeks between 2010 and 2012. Of the eligible 2421 mother-child pairs, 812 mother-son
pairs were included. Questionnaire data on medicine use were collected in first and third trimester and physical
examination at age 3 month was performed.
Ano-scrotal distance; measured from the centre of anus to the posterior base of scrotum (AGDas). Ano-cephalad
distance; measured from the centre of anus to the cephalad insertion of the penis (AGDap) and penile width;
measured at the base of the penis.
Results: Eighty seven women had used antifungal medicine during pregnancy. Maternal use of oral fluconazole
(n = 4) was associated with a 6.4 mm shorter AGDas (95% CI: -11.9;-0.9) in the male offspring. Use of antifungal
vaginal tablets (n = 21), was associated with a non-significantly shorter AGDas (−1.9 mm; 95% CI: -4.3; 0.5) whereas
exposure to vaginal cream (n = 23) was not associated to AGDas. Use of antifungal medicine in the window of genital
development between 8 and 14 weeks of gestation was associated with a larger reduction in AGDas than exposure
outside this window. Antifungal medicine intake was not associated with AGDap and penil width.
Conclusion: Our preliminary findings prompted us to hypothesize that maternal use of conazole antifungal
medication during pregnancy may affect the masculinization of male offspring. If confirmed, pregnant women
should be advised to use antifungal medicine with caution.
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Background
In pregnancy, the prevalence of vaginal candidiasis is in-
creased compared to those not pregnant [1]. Treatment
is antifungal compounds administered locally or system-
ically depending on the severity of symptoms [2]. In
Denmark, antifungal vaginal tablets and antifungal vaginal
cream with either the active ingredients miconazole or
clotrimazole (both imidiazoles) are recommended as
first treatment for vaginal candidiasis. Oral fluconazole
(triazole) is only recommended for severe cases when
the woman is pregnant [3–9]. Imidazole and triazole
compounds are anti-mycotic through inhibition of a
specific cytochrome P450 enzyme (CYP51) involved in
fungal cell wall synthesis, [10, 11] but they are also known
inhibitors of a range of other CYP enzymes including
those involved in androgen biosynthesis [11, 12]. Accord-
ingly, anti-androgenic properties have been demonstrated
for several conazole fungicides [12, 13].
In pregnancy, hormonal changes increase the risk of
vaginal candidiasis, [1, 14, 15] and as the fetus is particu-
larly vulnerable to endocrine disruption, use of anti-fun-
gal medication might affect development of the genitalia
[16–18]. A recent Danish study among 1,405,663 pregnant
women found an association between use of oral flucona-
zole during pregnancy and miscarriage [19]. Case reports
have linked high-dose, long-term treatment with oral
fluconazole during pregnancy to a pattern of skeletal
and craniofacial birth defects seen in the offspring. This
has raised concern regarding the safety of oral flucona-
zole use during pregnancy [20–23]. Other studies have
examined the association between maternal use of anti-
fungal medicine and malformations in the offspring, but
no consistent associations have been found [14, 24, 25].
Subtle signs of anti-androgen action have not been studied
in children whose mothers used anti-fungal medication
during pregnancy.
Anogenital distance (AGD: distance from anus to
genitals) is routinely used in animal toxicology studies
and is a sensitive test of exposure of the male fetus to
anti-androgenic agents [26–28]. In rodents, AGD has been
shown to reflect the amount of androgen to which a male
fetus is exposed in early development: in utero exposure
to lower levels of androgens results in a shorter AGD,
which is one marker of de-masculinisation [26, 28]. A
vulnerable fetal masculinisation programming window
(MPW) has been identified in rodent models in which
androgens must act to masculinise the components of
the reproductive tract and to allow the later complete
development. This MPW has been identified in human
to occur between gestation weeks 8–14 [29].
To our knowledge, no human studies have examined
the association between maternal exposure to antifungal
medicine and AGD in the male offspring. We therefore
prospectively investigated the association between systemic
or local use of antifungal medicine during pregnancy and
the subsequent AGD and penile width in the male offspring
at 3 months of age in the Odense Child Cohort (OCC)
study.
Methods
Newly pregnant women at gestational age 8–16 weeks
residing in Odense Municipality, Denmark, between 2010
and 2012 were recruited: at a voluntary information meet-
ing about ultrasound examinations; at their first antenatal
midwife visit; or at their ultrasound examination at
Odense University Hospital. All of the pregnant women in
the study completed two questionnaires, one during the
first and one during the third trimester [30]. Serum sam-
ples were collected twice and urine samples once during
pregnancy and stored in freezers at the Odense Patient
data Explorative Network (OPEN) [30]. The study was
carried out in accordance with the Helsinki Declaration II
and was approved by the Regional Scientific Ethical Com-
mittees for Southern Denmark (S-20090130).
Of the eligible population of 6707 pregnant women,
4017 women were informed about the study and 2421 live
born singletons with birth register data participated in the
study and are currently being followed up. Participants
were better educated (high school +1 year or more) and
more often of Danish origin than non-participants [30].
In the questionnaire administered during the first tri-
mester, participants were asked whether they had taken
any topical or systemic medications (both prescription
and over the counter) and if so to provide the name,
dose and gestational week/s of use of each named medi-
cation. In the second questionnaire (administered during
the third trimester) the women were asked to state
whether they had experienced specific diseases or symp-
toms (including vaginal candidiasis) during the last
3 months of pregnancy. Furthermore, the women were
asked to state whether they had ever used any type of
medication during their entire pregnancy. They were
asked to note names of medication, doses, total number of
days of use and in which gestational week(s) it was used.
The answers from both questionnaires were categorised
into: overall use of any type of antifungal medicine during
pregnancy; use of fluconazole oral tablets; use of antifun-
gal vaginal tablets (including antifungal vaginal cream if
used in combination with vaginal tablets); use of antifun-
gal vaginal cream only; and unspecific use of antifungal
medicine (women who had not specifically noted which
type of antifungal medicine they had used). In addition,
we categorised use of antifungal oral and vaginal tablets
into exposure in and outside the MPW (gestation weeks
8–14).
Three months after the expected date of birth, regardless
of actual gestational age at birth, the children were invited
for a clinical examination, which included measurements of
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length, weight and AGD. The two measurements of AGD,
and the measurement of penile width were made using a
Vernier caliper, which is the recommended instrument for
AGD measurement [31]. The shorter AGD measurement
was measured from the centre of anus to the posterior base
of scrotum (AGDas) and the longer from the centre of anus
to the cephalad insertion of the penis (AGDap). Penile
width was measured at the base of the penis. All of these
measurements were made three times and the arithmetic
mean was calculated. Expert-trained technicians performed
the examinations [30]. 13 boys had AGD measured by two
examiners. The coefficient of variation (CV) was 3% for all
the triplicate AGD measurements. Inter-examiner CV was
respectively 4%, 3% and 4% for AGDas, AGDap and penile
width indicating a high degree of consistency.
Statistical analysis
Use of antifungal medicine during pregnancy was catego-
rized into: no use (reference group); fluconazole oral tab-
lets; vaginal tablets; vaginal cream; and use of antifungal
medicine of unspecified type. Differences in distributions
of use of antifungal medicine according to population
characteristics were assessed by chi-square.
Univariate associations between use of antifungal
medicine during pregnancy, and AGD and penile width
at 3-months of age, were examined. Multiple linear regres-
sions were then used to adjust for potential confounding
factors. AGD values vary with age and weight of the child,
and because the clinical examination was scheduled to
take place three months after expected date of birth we
constructed a measure of ‘post-conceptional age’ defined
as the sum of gestational age at birth (in days) and the age
of the child at the AGD measurements (in days). Multiple
regression analyses were thus adjusted for the post-
conceptional age and individual weight-for-age standard
deviation score (Z-score) [32]. We examined several
potential confounding factors including maternal age,
maternal body mass index, ethnicity, smoking, alcohol
consumption as well as parity, socioeconomic status, ges-
tational age at the 3-month examination and birth weight.
None of these factors changed the estimated beta-
coefficient more than 10% and were therefore excluded
from the final models.
We evaluated the fit of the regression models by testing
the residuals for normality and by inspecting the residual
plots. All statistical analyses were conducted in STATA13.
P-values were considered significant when they were
<0.05, and 95% confidence intervals were calculated.
Results
A total of 2421 live born singletons with birth registry
data were included in the original OCC dataset. After
the initial exclusions, as shown in Fig. 1, the final dataset
consisted of 812 mother-son pairs with measurements at
3 months of whom there were 795 AGDap measurements,
810 AGDas measurements and 802 measurements of
penile width.
Pregnant women using anti-fungal medicine were more
often of non-European origin and had a shorter gestational
age, but there were no differences in age, parity, smoking
habit, alcohol intake, BMI or birth weight (Table 1).
Of the overall study population of 812 mother-son
pairs, 87 (11%) women had used antifungal medicine
during pregnancy (Table 1) of whom 4 women had been
treated with oral tablets containing fluconazole (a single
dose of 150 mg) within the MPW. In addition, 21
women had used vaginal tablets containing 500 mg to
1200 mg miconazole or clotrimazole of whom 11 had
used them in the MPW. Furthermore, of the 21 women
who had used vaginal tablets, 11 had used only antifun-
gal vaginal tablets and the other 10 had used them in
combination with antifungal vaginal cream. There were
23 women who had only used antifungal vaginal cream
Fig. 1 Numbers of infants included in Odense Child Cohort and in
the analysis
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(active ingredients miconazole or clotrimazole) and 39
women had used antifungal medicine but did not specify
type (Table 2 and Additional file 1).
After adjustment for weight-adjusted z-score and post-
conceptional age, boys prenatally exposed to oral flucon-
azole had a significantly shorter AGDas (−6.4 mm; 95%
CI: -11.9; −0.9) at their 3-month examination compared
to unexposed boys (Table 2, Figs. 2 and 3). In addition,
maternal use of antifungal vaginal tablets containing
miconazole or clotrimazole was marginally associated
with a shorter AGDas (−1.9 mm; 95% CI: -4.3; 0.5). Boys
exposed to vaginal tablets containing either miconazole or
clotrimazole in the MPW had shorter AGDas than those
exposed outside the MPW (Table 2). When dividing use
of vaginal tablets into only use of vaginal tablets and vagi-
nal tablet use in combination with cream, boys prenatally
exposed to only vaginal tablets had shorter AGDas than
those prenatally exposed to a combination (Table 2).
An association was found between unspecific antifungal
medicine use and penile width (−0.5 mm; 95%CI: -0.9;
−0.1) but no association was seen for penile width and
other exposure groups (see Additional file 1). No asso-
ciation was found between prenatal exposure to any
antifungal medicine and AGDap.
Discussion
Four pregnant women taking fluconazole orally gave birth
to boys with a significantly shorter AGDas (−6.4 mm) than
unexposed boys. In addition, maternal use of antifungal
vaginal tablets containing miconazole or clotrimazole
was associated with a shorter AGDas, although not sig-
nificantly, whereas use of the same compounds in the
form of vaginal creams did not affect AGDas. AGDap
and penile width were not affected apart from a shorter
penile width among boys to mothers with unspecific
use, which was probably due to chance. Interestingly,
use of antifungal medicine in the window of genital
development between 8 and 14 weeks of gestation was
associated with a larger reduction in AGDas than expos-
ure outside of this window. This is in accordance with
the sensitivity of this window to the effects of prenatal
anti-androgen exposure in rodent studies [27]. We ac-
knowledge that our rather preliminary findings are based
on four cases, but they are biologically plausible and of
public health importance as up to 20% of pregnant women
experience vaginal candidiasis. In addition, a 6.4 mm
shorter AGD corresponds to a 20% decrease and may be
of clinical importance as it has been associated with
abnormal adult male reproduction [33, 34].
This is to our knowledge the first human study to
examine the association between maternal exposure to
antifungal medicine and AGD in the offspring. Our findings
are biologically plausible, as conazole antifungals have
known anti-androgenic properties, [12] and exposure to
chemicals with anti-androgenic action (e.g. phthalates) have
been associated with shorter AGD in several human studies
[32, 35–38]. Rodent studies have shown that an impairment
of androgen action within the MPW can result abnormal
development and function of reproductive organs [27].
Hence, exposure to anti-androgenic chemicals, including
conazole antifungals, during the MPW have resulted in
Table 1 Population characteristics of 812 mother/boy pairs
included in the study according to antifungal medicine use in
percent
Population
characteristics
N = 812 (%)
No use of
antifungal medicine
N = 725
Use of some form
of antifungal
medicine N = 87
Maternal age (y)
<25 72(9) 9 9
25–35 555(72) 71 80
>35 150(19) 20 11
BMI (kg/m2)
<18.5 24(3) 3 6
18.5–24.9 495(61) 61 58
25–29.9 187(23) 23 22
> = 30 105(12) 13 14
Maternal ethnicity
European 602(95) 96* 88*
Non-European 32(5) 4* 12*
Maternal smoking
No 772(97) 97 97
Yes 25(3) 3 3
Alcohol consumption
No 565(91) 92 88
Yes 54(9) 8 12
Parity
Nulliparous 447(55) 55 53
Multiparous 364(45) 45 47
Socio economic statusa
Low 17(3) 2 5
Intermediate 189(30) 31 27
High 418(67) 67 68
Gestational age (weeks) at birth
<37 28(4) 4* 4*
37–40 538(68) 66* 79*
>40 231(29) 30* 18*
Birth weight (g)
<2500 g 18(2) 3 0
2500-3999 g 604(76) 75 79
> = 4000 g 175(22) 22 21
*p-value < 0.05 calculated by chi-square test
aLow = high school or less, Intermediate = high school +1–3 years further
education, High = high school +4 years or more further education
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hypospadias, cryptorchidism and shortened AGD in rodent
studies [26, 27].
Two large registry-based Danish studies found no
association between oral intake of fluconazole during
the first trimester and 15 different birth defects in the
offspring [24, 25], however, they did not measure
AGD. Similar findings have been reported in other
smaller studies [14, 15, 24], which also studied hypo-
spadias, but none of the studies measured AGD, which
may be a more sensitive marker of prenatal exposure
to anti-androgens [32].
The association between maternal use of antifungal va-
ginal tablets and AGD was weaker than among boys ex-
posed to oral treatment. This may be due to less potent
anti-androgenic action of miconazole and clotrimazole
and/or lower exposure from vaginal tablets. The same
reasoning may be used for the lack of effect of vaginal
cream exposure on AGDas, as exposure levels from
creams, is expected to be even lower. Miconazole in
vaginal tablets have been demonstrated to be absorbed
systemically [39]. Women using vaginal tablets without
combination with antifungal vaginal cream typically used
Table 2 Mean (SD) anogenital distance (AGDas) in mm in boys at three months according to maternal use of antifungal medicine
in pregnancy. Beta values represent adjusted mean difference calculated from multiple liniar regeression (95% confidence intervals,
95% CI) in AGD in boys whose mothers used antifungal medicine in pregnancy, compared to non-users
AGDas
N Mean (SD) mm βa mm 95% CI
No antifungal medicine use (reference) 723 36.1 (5.7) Reference
Vaginal tabletsb 21 35.0 (7.2) −1.9 (−4.3; 0.5)
Only vaginal tabletsc 11 33.5 (7.5) −3.0 (−6.3; 0.3)
Vaginal tablets in combination with creamc 10 36.7 (6.8) −0.7 (−4.1; 2.8)
Vaginal tablets in masculinisation programming windowd 11 35.0 (8.1) −2.2 (−5.5; 1.1)
Vaginal tablets outside the masculinisation programming windowd 10 35.0 (6.4) −1.6 (−5.0; 1.9)
Vaginal creamb only 23 35.9 (6.7) 0.1 (−2.3; 2.4)
Fluconazole oral tablets 4 28.7 (4.2)e −6.4e (−11.9; −0.9)e
Use of antifungal medicine but type not specified 39 35.5 (6.5) −0.9 (−2.7; 0.9)
aAdjusted for age and z-score for weight
bActive ingredients miconazole or clotrimazole
cSub-analysis where antifungal vaginal tablet use (N = 21) has been divided into “only vaginal tablet use” and “vaginal tablet used in combination with cream”
dSub-analysis where antifungal vaginal tablet use (N = 21) has been divided into “Vaginal tablets in masculinization programming window” and “Vaginal tablets
outside the masculinization programming window”
ep<0.05 after the adjusted oral tablets
Fig. 2 Mm reduction of AGDas (and 95% confidence intervals) according to maternal use of antifungal medicine adjusted for age and z-score for
weight from multiple linear regression
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tablets containing higher doses of miconazole or clotri-
mazole than women who used both tablets and cream.
Thus, the fetus may be exposed to a higher dose after
use of vaginal tablets alone compared to the combined
treatment of vaginal tables and cream which was seen by
a shorter ADGas in this group.
Participation rate was 43% [30] and only 11% of the
women reported use of antifungal medicine, which is
lower than the estimated 20% of all pregnant women
suffering vaginal candidiasis [14, 15]. This could be due
to the fact that our study population was higher edu-
cated and therefore more aware of the importance of
avoiding medication use during pregnancy. Information
about use of antifungal medicine was self-reported which
might have led to misclassification. This is, however, not
likely to be associated with AGD as the women were
unaware of this measure when answering the question-
naires leading to an underestimation of the association.
AGD measurements has acceptable intra- and inter-
examiner reliability, but with large inter-individual vari-
ation in measurements especially in AGDap measured
from the anus to the top of the cephalad insertion of the
penis. AGDap is therefore more dependent on the size
of the child, introducing a higher inaccuracy of the
measurement. Also, penile width is small and thus the
same absolute measurement error is of relatively larger
importance. Confounding by indication may explain our
findings, as the overgrowth of Candida albicans organ-
ism may be associated with a reduction in AGD, rather
than the use of antifungal medication. We adjusted for
relevant confounders but we cannot exclude the possibility
of residual confounding from for example co-exposure
to other environmental chemicals, lifestyle or health
behavior.
In male rodents, the shortened AGD persists into
adulthood confirming that interference of androgenic ac-
tivity permanently alters the reproductive tissues [29]. In
cross-sectional studies among adult men, AGD has been
shown to have a significant positive association with sperm
count [34]. In fact, AGD is now considered part of the
spectrum of male intrauterine testicular disruption called
the testicular dysgenesis syndrome (TDS) [18]. Therefore,
the observed reduction in AGD may have potential long-
term consequences for male reproductive health.
Fig. 3 Column scatterplot of AGDas in mm among boys not prenatally exposed to antifungal medicine (green dots), boys prenatally exposed to
antifungal vaginal tablets outside the MPW (red dots), boys prenatally exposed to antifungal vaginal tablets in the MPW (blue dots), and boys
prenatally exposed to oral fluconazole (purple dots)
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Conclusion
Based on our findings that four pregnant women taking
fluconazole orally gave birth to boys with a significantly
shorter AGD we hypothesize that maternal use of anti-
fungal medication may cause anti-androgenic effects.
Further studies on maternal antifungal use during preg-
nancy are needed. In the interim, pregnant women
should be advised to use antifungal medicine with
caution.
Additional file
Additional file 1: Table S1. Use of antifungal vaginal tablets (active
ingredients clotrimazole or miconazole) and oral fluconazole and in
relation to anogenital distance (AGDas, AGDap) and penile width
measurements among 25 mother/boy pairs. Table S2. Mean (SD) penile
width in mm in boys at three months according to maternal use of
antifungal medicine in pregnancy. Beta values represent adjusted mean
difference (95% confidence intervals, 95% CI) in penile width in boys
whose mothers used antifungal medicine in pregnancy, and non-users.
(DOCX 110 kb)
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